Literature DB >> 12678535

Apolipoprotein D expression in benign and malignant prostate tissues.

J C Rodríguez1, M Díaz, L O González, J Sánchez, M T Sánchez, A M Merino, F Vizoso.   

Abstract

BACKGROUND: Apolipoprotein D (ApoD), a protein component of the human plasma lipid transport system, is an androgen regulated protein in both breast and prostate cancer cell lines.
METHODS: Here we examined, by immunohistochemical assay, the ApoD expression in normal, benign and malignant prostate tissues.
RESULTS: ApoD was detected in the two analyzed normal prostate tissues, in 16 (94.1%) of 17 benign prostatic hyperplasias, and in 36 (63.1%) of 57 prostate carcinomas. In prostate carcinomas, ApoD immunostaining values did not show significant relationship neither with age of the patients, stage and histologic grade of the tumors, nor with preoperative serum levels of prostatic specific antigen (PSA). However, ApoD-negative immunostaining predicted shorter survival duration in the subgroup of 46 patients with nonresectable prostate cancer (p = 0.02).
CONCLUSIONS: Our results led us to consider that Apo D expression by prostate carcinomas migth be of clinical usefulness for identificating lesions with different evolution.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 12678535

Source DB:  PubMed          Journal:  Int J Surg Investig        ISSN: 1028-5229


  3 in total

1.  A basal stem cell signature identifies aggressive prostate cancer phenotypes.

Authors:  Bryan A Smith; Artem Sokolov; Vladislav Uzunangelov; Robert Baertsch; Yulia Newton; Kiley Graim; Colleen Mathis; Donghui Cheng; Joshua M Stuart; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-12       Impact factor: 11.205

2.  Expression and potential role of apolipoprotein D on the death-survival balance of human colorectal cancer cells under oxidative stress conditions.

Authors:  Raquel Bajo-Grañeras; Jesús Crespo-Sanjuan; Rosa M García-Centeno; José Antonio Garrote-Adrados; Gabriel Gutierrez; Manuel García-Tejeiro; Beatriz Aguirre-Gervás; María D Calvo-Nieves; Rosa Bustamante; Maria D Ganfornina; Diego Sanchez
Journal:  Int J Colorectal Dis       Date:  2013-01-08       Impact factor: 2.571

3.  Characterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y.

Authors:  Petra Massoner; Karl G Kugler; Karin Unterberger; Ruprecht Kuner; Laurin A J Mueller; Maria Fälth; Georg Schäfer; Christof Seifarth; Simone Ecker; Irmgard Verdorfer; Armin Graber; Holger Sültmann; Helmut Klocker
Journal:  PLoS One       Date:  2013-02-04       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.